Mark Campbell
Clinical Doctoral Research Fellow
Mark joined Oxford Population Health during the COVID-19 pandemic as a clinical research fellow with the RECOVERY (Randomised Evaluation of COVID-19 Therapy) trial.
He is now studying for a DPhil in Population Health, with his research focusing on the detailed clinical effects and biological mechanisms of COVID-19 immunomodulatory therapies, evaluated through linking new individual participant level clinical, biochemical, virological and multi-omics data with the RECOVERY trial database.
Mark graduated with degrees in Medicine and Clinical Epidemiology from Newcastle University in 2013 and moved to Oxford where he now works as an Infectious Diseases and Microbiology doctor.
Recent publications
-
Clinical trial results in context: comparison of baseline characteristics and outcomes of 38,510 RECOVERY trial participants versus a reference population of 346,271 people hospitalised with COVID-19 in England.
Journal article
Pessoa-Amorim G. et al, (2024), Trials, 25